Oculus Innovative Sciences to Rollout Five New Microcyn(R) Technology-Based Products in Singapore and Malaysia

Oculus Innovative Sciences to Rollout Five New Microcyn(R) Technology-Based
Products in Singapore and Malaysia

PETALUMA, Calif., April 10, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in over 20
countries, today announced that the company's partner in that region, Dyamed
Biotech Pte. Ltd, is initiating rollout of five new Microcyn® Technology-based
products in Singapore and Malaysia, both in the hospital and consumer
markets.The five products, which include Dermacyn™ BabyGuard, Dermacyn
DermaGuard, Dermacyn SkinGuard Solution, Dermacyn SkinGuard Hydrogel and
Dermacyn Wound Care Hydrogel, will be rolled out sequentially with all
products commercialized by year's end.

Bruce Thornton, executive vice president of Oculus said: "As part of Oculus'
ongoing growth strategy, we have implemented three near-term tactics:First,
expansion of our Microcyn-based products portfolio, which currently numbers
over 100 product SKUs.Secondly, the addition of new international partners
and distributors.And finally, expanding our international commercial
footprint from the current level of 21 countries to near 30 in a year's
time.Growth in the Asian countries, including Singapore and Malaysia, present
an excellent opportunity to not only grow these international sales, but just
as importantly—allows us to bring improved patient outcomes via the Microcyn
Technology to a larger global population."

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in over 20
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard ofpatient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found
atwww.oculusis.com.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "initiating," "will be" and"expansion,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
        
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
 
Press spacebar to pause and continue. Press esc to stop.